Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study (updated)

Acadia Pharmaceuticals

11/03/2024 20:46

(Adds details in paragraphs 1-2, background throughout)
       March 11 (Reuters) - Acadia Pharmaceuticals  ACAD.O 
said on Monday its antipsychotic drug failed to significantly
improve negative symptoms of schizophrenia, including poor
socialization and lack of motivation, in a late-stage study.
    The company said it does not plan to conduct further
clinical trials with its drug, pimavanserin.
    Schizophrenia is a chronic brain disorder characterized by
delusions, disorganized speech, trouble with thinking and lack
of motivation, and affects less than 1% of the U.S. population,
according to the American Psychiatric Association.   
    The company's drug, sold under the brand name Nuplazid, is
approved in the U.S. for the treatment of hallucinations and
delusions associated with Parkinson's disease psychosis.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shweta
Agarwal)
 ((Mariam.ESunny@thomsonreuters.com;))